

Lupin Ltd. Therapeutic and Drug Pipeline Review

Global Lupin Ltd. Drugs and Companies Pipeline Review 2017

PUNE, INDIA, February 28, 2017 /EINPresswire.com/ -- The report provides comprehensive information on the therapeutics under development by Lupin Limited, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.



WISE GUY
R E P O R T S

Norah Trent Partner Relations & Marketing Manager

✉ sales@wiseguyreports.com

☎ Ph: +1-646-845-9349 (US) Ph: +44 208 133 9349 (UK)

🌐 <https://www.linkedin.com/company/4828928>

🐦 <https://twitter.com/WiseGuyReports>

📘 <https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts>

Wise.Guy.

Get Sample Report @ <https://www.wiseguyreports.com/sample-request/619241-lupin-limited-product-pipeline-review-2016>

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Lupin Limited
- The report provides overview of Lupin Limited including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Lupin Limited's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Lupin Limited's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

- Evaluate Lupin Limited's strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Lupin Limited
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Lupin Limited's pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Content: Key Points

Table of Contents 2

List of Tables 4

List of Figures 5

Lupin Limited Snapshot 6

Lupin Limited Overview 6

Key Information 6

Key Facts 6

Lupin Limited - Research and Development Overview 7

Key Therapeutic Areas 7

Lupin Limited - Pipeline Review 10

Pipeline Products by Stage of Development 10

Pipeline Products - Monotherapy 11

Lupin Limited - Pipeline Products Glance 12

Lupin Limited - Late Stage Pipeline Products 12

Phase III Products/Combination Treatment Modalities 12

Lupin Limited - Clinical Stage Pipeline Products 13

Phase II Products/Combination Treatment Modalities 13

Phase I Products/Combination Treatment Modalities 14

Lupin Limited - Early Stage Pipeline Products 15

Preclinical Products/Combination Treatment Modalities 15

Discovery Products/Combination Treatment Modalities 16

Lupin Limited - Unknown Stage Pipeline Products 17

Unknown Products/Combination Treatment Modalities 17

Lupin Limited - Drug Profiles 18

Biosimilar for Oncology 18

Product Description 18

Mechanism of Action 18

R&D Progress 18

etanercept biosimilar 19

Product Description 19

Mechanism of Action 19

R&D Progress 19

LND-101001 20

Product Description 20

Access Report @ <https://www.wiseguyreports.com/reports/619241-lupin-limited-product-pipeline-review-2016>

Get in touch:

LinkedIn: www.linkedin.com/company/4828928

Twitter: <https://twitter.com/WiseGuyReports>

Facebook: <https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts>

Norah Trent

wiseguyreports

+1 646 845 9349 / +44 208 133 9349

email us here

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2018 IPD Group, Inc. All Right Reserved.